PMID- 12088449
OWN - NLM
STAT- MEDLINE
DCOM- 20020730
LR  - 20210527
IS  - 0003-9985 (Print)
IS  - 0003-9985 (Linking)
VI  - 126
IP  - 7
DP  - 2002 Jul
TI  - Clinical laboratory assays for HER-2/neu amplification and overexpression: 
      quality assurance, standardization, and proficiency testing.
PG  - 803-8
AB  - OBJECTIVE: To present and contrast the results of immunohistochemistry and 
      fluorescence in situ hybridization (FISH) proficiency testing surveys for 
      HER-2/neu, as conducted by the Cell Markers and Cytogenetics Committees of the 
      College of American Pathologists. DESIGN: During the past 2 years, unstained 
      sections from invasive breast carcinomas have been used for both 
      immunohistochemistry and interphase FISH proficiency surveys. In most instances, 
      the same cases were used for both the Cell Markers and Cytogenetics surveys. 
      Additional data regarding interpretative variability for immunohistochemistry 
      surveys have also been captured. RESULTS: The number of laboratories performing 
      FISH for HER-2/neu testing doubled during the 2-year period. The results of FISH 
      testing have been remarkably concordant for laboratories submitting results. In 
      contrast, the results of immunohistochemistry testing continue to highlight 
      substantial variability among laboratories evaluating the same cases. The data 
      show that this variability is at least in part due to variability in 
      interpretation among observers, as well as inherent differences between 
      immunohistochemistry and FISH techniques. CONCLUSIONS: College of American 
      Pathologists proficiency survey programs provide useful information about 
      clinical testing for HER-2/neu amplification/overexpression.
CN  - Cell Markers And Cytogenetics Committees College Of American Pathologists
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/genetics/metabolism/pathology
MH  - Carcinoma/genetics/metabolism/pathology
MH  - Clinical Laboratory Techniques/*methods/standards
MH  - Gene Amplification/*genetics
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Quality Assurance, Health Care
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - Reproducibility of Results
MH  - Societies, Medical
RF  - 53
EDAT- 2002/06/29 10:00
MHDA- 2002/07/31 10:01
CRDT- 2002/06/29 10:00
PHST- 2002/06/29 10:00 [pubmed]
PHST- 2002/07/31 10:01 [medline]
PHST- 2002/06/29 10:00 [entrez]
AID - 10.5858/2002-126-0803-CLAFHN [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2002 Jul;126(7):803-8. doi: 10.5858/2002-126-0803-CLAFHN.